During the recent session, Ocugen Inc (NASDAQ:OCGN)’s traded shares were 0.89 million, with the beta value of the company hitting 3.87. At the last check today, the stock’s price was $0.74, reflecting an intraday gain of 5.08% or $0.04. The 52-week high for the OCGN share is $2.11, that puts it down -185.14 from that peak though still a striking 17.57% gain since the share price plummeted to a 52-week low of $0.61. The company’s market capitalization is $214.84M, and the average intraday trading volume over the past 10 days was 3.47 million shares, and the average trade volume was 4.66 million shares over the past three months.
Ocugen Inc (OCGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. OCGN has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.05.
Ocugen Inc (NASDAQ:OCGN) trade information
Ocugen Inc (OCGN) registered a 5.08% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.08% in intraday trading to $0.74, hitting a weekly high. The stock’s 5-day price performance is 3.65%, and it has moved by 1.30% in 30 days. Based on these gigs, the overall price performance for the year is 21.05%. The short interest in Ocugen Inc (NASDAQ:OCGN) is 58.88 million shares and it means that shorts have 12.91 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 85.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.5 and $6 respectively. As a result, OCGN is trading at a discount of -710.81% off the target high and -372.97% off the low.
Ocugen Inc (OCGN) estimates and forecasts
In the rating firms’ projections, revenue will decrease -40.02% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 300k as predicted by 4 analyst(s). As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.42M and 1.01M respectively. In this case, analysts expect current quarter sales to shrink by -78.86% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 41.20%. While earnings are projected to return 23.08% in 2025, the next five years will return 4.71% per annum.
OCGN Dividends
Ocugen Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ocugen Inc (NASDAQ:OCGN)’s Major holders
Ocugen Inc insiders own 1.28% of total outstanding shares while institutional holders control 24.99%, with the float percentage being 25.32%. BLACKROCK INC. is the largest shareholder of the company, while 147.0 institutions own stock in it. As of 2024-06-30, the company held over 17.92 million shares (or 6.9665% of all shares), a total value of $27.78 million in shares.
The next largest institutional holding, with 15.52 million shares, is of VANGUARD GROUP INC’s that is approximately 6.0339% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $24.06 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ocugen Inc (OCGN) shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 9.07 shares. This amounts to just over 3.11 percent of the company’s overall shares, with a $6.61 million market value. The same data shows that the other fund manager holds slightly less at 8.7, or about 2.99% of the stock, which is worth about $6.34 million.
